HEPA
Hepion Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-07
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.19
P/S
0.00
EV/EBITDA
0.14
DCF Value
$0.17
FCF Yield
-511.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-242.0%
ROA
-269.6%
ROIC
-147.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-656.9K | $1.40 |
| FY 2025 | $0.00 | $-8.3M | $-0.88 |
| Q3 2025 | $0.00 | $-472.5K | $-0.04 |
| Q2 2025 | $0.00 | $-1.0M | $-0.09 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$70.00
Target (Median)
$70.00
Target Range
$70.00 - $70.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.61
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.